Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 2
1989 1
1991 2
1993 2
1994 2
1996 1
1997 1
1998 1
2001 1
2002 1
2008 2
2009 1
2014 1
2015 2
2018 2
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact.
Braunschmid T, Kührer I, Mittlböck M, Westerhoff M, Kappel-Latif S, Brammen L, Krishnadath KK, Phillips WA, Gnant M, Kandioler D. Braunschmid T, et al. Among authors: kuhrer i. Ann N Y Acad Sci. 2018 Dec;1434(1):46-53. doi: 10.1111/nyas.13947. Epub 2018 Aug 15. Ann N Y Acad Sci. 2018. PMID: 30112858 Free article. Review.
[Interferon therapy in multiple myeloma].
Ludwig H, Scheithauer W, Kührer I, Kuzmits R, Gisslinger G, Linkesch W, Zielinski C, Fritz E. Ludwig H, et al. Among authors: kuhrer i. Onkologie. 1988 Aug;11(4):192-6. doi: 10.1159/000216520. Onkologie. 1988. PMID: 3054670 German.
[The treatment of multiple myeloma].
Ludwig H, Kührer I. Ludwig H, et al. Among authors: kuhrer i. Wien Klin Wochenschr. 1994;106(14):448-54. Wien Klin Wochenschr. 1994. PMID: 7941591 Review. German.
The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kührer I, Illiger HJ, Kempf B, Reichle A, Föller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ. Bokemeyer C, et al. Among authors: kuhrer i. Semin Oncol. 1998 Apr;25(2 Suppl 4):24-32; discussion 45-8. Semin Oncol. 1998. PMID: 9578059 Review.
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases-a phase II study.
Piringer G, Gruenberger T, Thaler J, Kührer I, Kaczirek K, Längle F, Viragos-Toth I, Amann A, Eisterer W, Függer R, Andel J, Pichler A, Stift J, Sölkner L, Gnant M, Öfner D. Piringer G, et al. Among authors: kuhrer i. Front Oncol. 2023 Aug 9;13:1231600. doi: 10.3389/fonc.2023.1231600. eCollection 2023. Front Oncol. 2023. PMID: 37621684 Free PMC article.
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.
Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, Pober M, Zielinski CC, Steger GG; Austrian Fulvestrant Registry. Bartsch R, et al. Breast Cancer Res Treat. 2009 May;115(2):373-80. doi: 10.1007/s10549-008-0132-0. Epub 2008 Jul 26. Breast Cancer Res Treat. 2009. PMID: 18661231 Clinical Trial.
TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.
Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, Hofbauer F, Samonigg H, Gnant M, Teleky B, Kührer I; p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG). Kandioler D, et al. Among authors: kuhrer i. EBioMedicine. 2015 Jun 8;2(8):825-30. doi: 10.1016/j.ebiom.2015.06.003. eCollection 2015 Aug. EBioMedicine. 2015. PMID: 26425688 Free PMC article. Clinical Trial.
[Germ cell tumors of the testis].
Krainer M, Kührer I, Kratzik C. Krainer M, et al. Among authors: kuhrer i. Wien Klin Wochenschr. 1994;106(2):37-44. Wien Klin Wochenschr. 1994. PMID: 8146994 Review. German.
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.
Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, Schoppmann SF, Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D; Pancho trialists and for the Medical University of Vienna p53research group. Kappel-Latif S, et al. Among authors: kuhrer i. Eur Surg. 2018;50(4):160-166. doi: 10.1007/s10353-018-0527-z. Epub 2018 Jun 11. Eur Surg. 2018. PMID: 30559831 Free PMC article.
23 results